ABL1 and acute lymphoblastic leukemia: In both mouse models and human patients, BCR-ABL ALL can be effectively managed by continuous administration of the BCR-ABL/Src inhibitor dasatinib (Gruber et al, 2009; Boulos et al, 2011).